Recurrent Pregnancy Loss
0
Pipeline Programs
4
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Colorado TherapeuticsCO - Louisville
1 programGenomic Predictors of Recurrent Pregnancy LossN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Colorado TherapeuticsGenomic Predictors of Recurrent Pregnancy Loss
PfizerLow molecular weight heparin and low dose aspirin
Clinical Trials (2)
Total enrollment: 588 patients across 2 trials
Genomic Predictors of Recurrent Pregnancy Loss
Start: Sep 2021Est. completion: Dec 2026500 patients
N/ARecruiting
Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT
Start: Mar 2000Est. completion: Sep 200588 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 588 patients
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.